KYUSHU UNIVERSITY
- Country
- 🇯🇵Japan
- Ownership
- Private
- Established
- 1903-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.kyushu-u.ac.jp/en
Clinical Trials
161
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (159 trials with phase data)• Click on a phase to view related trials
Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors
- Conditions
- Pediatric Solid TumorsRefractory/Relapse Neuroblastoma
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Kyushu University
- Target Recruit Count
- 56
- Registration Number
- NCT05608148
- Locations
- 🇯🇵
Kyushu University Hospital, Fukuoka, Japan
GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites
- Conditions
- Gastric CancerPancreatic Cancer
- Interventions
- Biological: Phase I partBiological: Phase II part
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Kyushu University
- Target Recruit Count
- 96
- Registration Number
- NCT05438459
- Locations
- 🇯🇵
Kyushu University Hospital, Fukuoka-shi, Fukuoka, Japan
Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI)
- Conditions
- CTEPH
- Interventions
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Kyushu University
- Target Recruit Count
- 74
- Registration Number
- NCT04730037
- Locations
- 🇯🇵
Kyushu University Hospital, Fukuoka, Japan
Effective Iodide Therapy for Untreated Patients With Graves' Hyperthyroidism Avoiding Thionamide Drugs With Many Side Effects
- First Posted Date
- 2020-12-28
- Last Posted Date
- 2020-12-28
- Lead Sponsor
- Kyushu University
- Target Recruit Count
- 504
- Registration Number
- NCT04686006
PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of Prematurity
- Conditions
- Retinopathy of Prematurity
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Kyushu University
- Target Recruit Count
- 24
- Registration Number
- NCT04621136
- Locations
- 🇯🇵
University Hospital of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
🇯🇵Yamaguchi University Hospital, Ube, Yamaguchi, Japan
🇯🇵Kyushu University Hospital, Fukuoka, Japan
- Prev
- 1
- 2
- 3
- Next
News
Five-Year Study Shows Aflibercept Treat-and-Extend Regimen Maintains Vision in Neovascular AMD Patients
• A multicenter Japanese study demonstrates that aflibercept using a treat-and-extend regimen maintained baseline visual acuity and significantly reduced central macular thickness in neovascular AMD patients over five years. • Researchers identified smaller greatest linear dimension (GLD) as the only independent risk factor associated with better vision outcomes after five years of treatment (p=0.0024). • The study revealed patients required fewer injections after the first year, though 33% of discontinued cases experienced recurrence, with higher recurrence rates in those who had received more total injections.